These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 17724438)

  • 41. Bone marrow transplantation for Fanconi anemia using fludarabine-based conditioning.
    Stepensky P; Shapira MY; Balashov D; Trakhtman P; Skorobogatova E; Rheingold L; Brooks R; Revel-Vilk S; Weintraub M; Stein J; Maschan A; Or R; Resnick IB
    Biol Blood Marrow Transplant; 2011 Sep; 17(9):1282-8. PubMed ID: 21220033
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Successful bone marrow transplantation for IPEX syndrome after reduced-intensity conditioning.
    Rao A; Kamani N; Filipovich A; Lee SM; Davies SM; Dalal J; Shenoy S
    Blood; 2007 Jan; 109(1):383-5. PubMed ID: 16990602
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Successful umbilical cord blood transplantation in a child with dyskeratosis congenita after a fludarabine-based reduced-intensity conditioning regimen.
    Nobili B; Rossi G; De Stefano P; Zecca M; Giorgiani G; Perrotta S; Canazzio A; Locatelli F
    Br J Haematol; 2002 Nov; 119(2):573-4. PubMed ID: 12406104
    [No Abstract]   [Full Text] [Related]  

  • 44. Adenovirus infection rates in pediatric recipients of alternate donor allogeneic bone marrow transplants receiving either antithymocyte globulin (ATG) or alemtuzumab (Campath).
    Myers GD; Krance RA; Weiss H; Kuehnle I; Demmler G; Heslop HE; Bollard CM
    Bone Marrow Transplant; 2005 Dec; 36(11):1001-8. PubMed ID: 16184180
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group.
    Stilgenbauer S; Zenz T; Winkler D; Bühler A; Schlenk RF; Groner S; Busch R; Hensel M; Dührsen U; Finke J; Dreger P; Jäger U; Lengfelder E; Hohloch K; Söling U; Schlag R; Kneba M; Hallek M; Döhner H;
    J Clin Oncol; 2009 Aug; 27(24):3994-4001. PubMed ID: 19597025
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategy.
    Shore T; Harpel J; Schuster MW; Roboz GJ; Leonard JP; Coleman M; Feldman EJ; Silver RT
    Biol Blood Marrow Transplant; 2006 Aug; 12(8):868-75. PubMed ID: 16864057
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Outcomes of alemtuzumab-based reduced intensity conditioning stem cell transplantation using unrelated donors for myelodysplastic syndromes.
    Lim ZY; Ho AY; Ingram W; Kenyon M; Pearce L; Czepulkowski B; Devereux S; Duarte RF; Pagliuca A; Mufti GJ
    Br J Haematol; 2006 Oct; 135(2):201-9. PubMed ID: 16939494
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias.
    Burke JM; Caron PC; Papadopoulos EB; Divgi CR; Sgouros G; Panageas KS; Finn RD; Larson SM; O'Reilly RJ; Scheinberg DA; Jurcic JG
    Bone Marrow Transplant; 2003 Sep; 32(6):549-56. PubMed ID: 12953125
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Busulfan, fludarabine, and alemtuzumab as a reduced toxicity regimen for children with malignant and nonmalignant diseases improves engraftment and graft-versus-host disease without delaying immune reconstitution.
    Law J; Cowan MJ; Dvorak CC; Musick L; Long-Boyle JR; Baxter-Lowe LA; Horn B
    Biol Blood Marrow Transplant; 2012 Nov; 18(11):1656-63. PubMed ID: 22609040
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Delayed attainment of full donor chimaerism following alemtuzumab-based reduced-intensity conditioning haematopoeitic stem cell transplantation for acute myeloid leukaemia and myelodysplastic syndromes is associated with improved outcomes.
    Lim ZY; Pearce L; Ho AY; Barber L; Ingram W; Usai M; Tobal K; Devereux S; Pagliuca A; Mufti GJ
    Br J Haematol; 2007 Aug; 138(4):517-26. PubMed ID: 17608767
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia.
    Alinari L; Lapalombella R; Andritsos L; Baiocchi RA; Lin TS; Byrd JC
    Oncogene; 2007 May; 26(25):3644-53. PubMed ID: 17530018
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Post-transplant lymphoproliferative disease following reduced intensity conditioning transplants incorporating alemtuzumab.
    Bokhari S; Das-Gupta E; Russell N; Byrne J
    Bone Marrow Transplant; 2008 Aug; 42(4):281-2. PubMed ID: 18490912
    [No Abstract]   [Full Text] [Related]  

  • 53. Reduced intensity conditioning and allogeneic stem cell transplantation after salvage therapy integrating alemtuzumab for patients with relapsed peripheral T-cell non-Hodgkin's lymphoma.
    Wulf GG; Hasenkamp J; Jung W; Chapuy B; Truemper L; Glass B
    Bone Marrow Transplant; 2005 Aug; 36(3):271-3. PubMed ID: 15937499
    [No Abstract]   [Full Text] [Related]  

  • 54. Chronic lymphocytic leukaemia. Current strategy and new perspectives of treatment.
    Rai KR
    Haematologica; 1999 Jun; 84 Suppl EHA-4():94-5. PubMed ID: 10907481
    [No Abstract]   [Full Text] [Related]  

  • 55. Allogeneic stem cell transplantation in a patient with dyskeratosis congenita after conditioning with low-dose cyclophosphamide and anti-thymocyte globulin.
    Ayas M; Al-Musa A; Al-Jefri A; Al-Seraihi A; Al-Mahr M; Rifai S; El-Solh H
    Pediatr Blood Cancer; 2007 Jul; 49(1):103-4. PubMed ID: 16317729
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bone marrow transplant for dyskeratosis congenita.
    Lau YL; Ha SY; Chan CF; Lee AC; Liang RH; Yuen HL
    Br J Haematol; 1999 May; 105(2):571. PubMed ID: 10233444
    [No Abstract]   [Full Text] [Related]  

  • 57. [Allogeneic stem cell transplantation with fludarabine/melphalan (non-TBI and non-BU/CY) for patients aged 50 or more].
    Inamoto Y; Kuwatsuka Y; Tsujimura A; Tokunaga M; Oba T; Miyamura K; Kodera Y
    Rinsho Ketsueki; 2006 Jan; 47(1):9-15. PubMed ID: 16479977
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Alemtuzumab markedly reduces chronic GVHD without affecting overall survival in reduced-intensity conditioning sibling allo-SCT for adults with AML.
    Malladi RK; Peniket AJ; Littlewood TJ; Towlson KE; Pearce R; Yin J; Cavenagh JD; Craddock C; Orchard KH; Olavarria E; McQuaker G; Collin M; Marks DI;
    Bone Marrow Transplant; 2009 May; 43(9):709-15. PubMed ID: 19029965
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma.
    Nagler A; Slavin S; Varadi G; Naparstek E; Samuel S; Or R
    Bone Marrow Transplant; 2000 May; 25(10):1021-8. PubMed ID: 10828860
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Fatal Hemorrhagic Gastrointestinal Angioectasia after Bone Marrow Transplantation for Dyskeratosis Congenita.
    Imai J; Suzuki T; Yoshikawa M; Dekiden M; Nakae H; Nakahara F; Tsuda S; Mizukami H; Koike J; Igarashi M; Yabe H; Mine T
    Intern Med; 2016; 55(23):3441-3444. PubMed ID: 27904106
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.